Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients

Journal of Gastroenterology

Volumn 47, Issue 2, 2012, Pages 169-178

  Kanto, Tatsuya ^a   Inoue, Michiyo ^a   Oze, Tsugiko ^a   Miyazaki, Masanori ^a   Sakakibara, Mitsuru ^a,b   Kakita, Naruyasu ^a,b   Matsubara, Tokuhiro ^a   Higashitani, Koyo ^a,c   Hagiwara, Hideki ^d   Iio, Sadaharu ^c   Katayama, Kazuhiro ^e   Mita, Eiji ^f   Kasahara, Akinori ^g   Hiramatsu, Naoki ^a   Takehara, Tetsuo ^a   Hayashi, Norio ^a,d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CENTER FOR ADULT DISEASES   (Japan)

^c Higashiosaka City General Hospital   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Early virological response; Plasmacytoid dendritic cells; Regulatory T cells

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGICAL RESPONSE; DENDRITIC CELL; DRUG COMBINATION; HEPATITIS C VIRUS; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET COUNT; RIBAVIRIN; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84862310666     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0466-y     Document Type: Article

References (36)

1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(Suppl 3):S206-14.
2. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2010:140: 1182-8.e1.
3. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009;136:1618-28.e2.
4. Jacobson IM. Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy. Clin Gastroenterol Hepatol. 2009;7:921-30.
5. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17-27.
6. Poynard T. Treatment of hepatitis C virus: the first decade. Semin Liver Dis. 2004;24(Suppl 2):19-24. (Pubitemid 39180702)
7. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-52. (Pubitemid 37052151)
8. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425-33. (Pubitemid 41111423)
9. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-97.
10. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745-54.
11. Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med. 2006;45:183-91.
12. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002;123:1070-83.
13. Pachiadakis I, Chokshi S, Cooksley H, Farmakiotis D, Sarrazin C, Zeuzem S, et al. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol. 2009;131:415-25.
14. Itose I, Kanto T, Inoue M, Miyazaki M, Miyatake H, Sakakibara M, et al. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients. J Med Virol. 2007;79:511-21. (Pubitemid 46564349)
15. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology. 2000;32:654-9.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20. (Pubitemid 24166476)
17. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
18. Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, et al. Pegylated interferon alpha-2b (Peg-IFN alpha2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat. 2009;16:578-85.
19. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, et al. Ribavirin dose reduction raises relapse rate dosedependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat. 2009;16:586-94.
20. Itose I, Kanto T, Kakita N, Takebe S, Inoue M, Higashitani K, et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat. 2009;16:844-52.
21. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol. 1999;162:5584-91. (Pubitemid 29307172)
22. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38:1437-48. (Pubitemid 37466970)
23. Soldevila B, Alonso N, Martinez-Arconada MJ, Morillas RM, Planas R, Sanmarti AM, et al. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(?) CD25(?) CD127(low/-) FoxP3(?) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. J Viral Hepat. 2011;18:384-92.
24. Akiyama M, Ichikawa T, Miyaaki H, Motoyoshi Y, Takeshita S, Ozawa E, et al. Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C. Intervirology. 2010;53:154-60.
25. Burton JR Jr, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, et al. Prospective analysis of effector and regulatory CD4? T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol. 2008;49:329-38.
26. Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, et al. PD-L1 negatively regulates CD4?CD25? Foxp3?Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119:551-64.
27. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4? T reg cells. J Exp Med. 2006;203: 1701-11. (Pubitemid 44036276)
28. Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol. 2011;54:604-11.
29. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-9.
30. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8:594-606.
31. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol. 2001;166:2961-9. (Pubitemid 33117291)
32. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105:7034-9. (Pubitemid 351754525)
33. Mengshol JA, Golden-Mason L, Castelblanco N, Im KA, Dillon SM, Wilson CC, et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut. 2009;58:964-73.
34. Cicinnati VR, Kang J, Sotiropoulos GC, Hilgard P, Frilling A, Broelsch CE, et al. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J Gen Virol. 2008;89:1243-53.
35. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403-10. (Pubitemid 46185701)
36. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-9.